ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • interstitial lung disease and Musculoskeletal
  • interstitial lung disease and mycophenolate mofetil
  • Interstitial lung disease and myopathy
  • interstitial lung disease and myositis
  • interstitial lung disease and outcome measures
  • interstitial lung disease and polymyositis
  • interstitial lung disease and polymyositis/dermatomyositis (PM/DM)
  • interstitial lung disease and population studies
  • interstitial lung disease and prognostic factors
  • interstitial lung disease and pulmonary complications
  • interstitial lung disease and pulmonary fibrosis
  • interstitial lung disease and rheumatoid arthritis
  • interstitial lung disease and rheumatoid arthritis (RA)
  • interstitial lung disease and rituximab
  • interstitial lung disease and scleroderma
  • interstitial lung disease and serologic tests
  • interstitial lung disease and Sjogren's syndrome
  • interstitial lung disease and SSc-ILD
  • interstitial lung disease and synthetase syndrome
  • interstitial lung disease and systematic review
  • interstitial lung disease and systemic lupus erythematosus (SLE)
  • interstitial lung disease and systemic sclerosis
  • Interstitial lung disease and tofacitinib
  • interstitial lung disease and treatment
  • interstitial lung disease and ulcers
  • interstitial lung disease and ultrasound
  • interstitial lung disease and vascular damage
  • interstitial lung disease and vasculitis
  • Intervention
  • Intervention and Musculoskeletal
  • Intervention and physical activity
  • Intestinal flora
  • intima medial thickness
  • intima medial thickness and large vessel vasculitis
  • intima medial thickness and meta-analysis
  • intima medial thickness and rheumatoid arthritis (RA)
  • intima medial thickness and systemic lupus erythematosus (SLE)
  • intima medial thickness and tumor necrosis factor (TNF)
  • intima medial thickness and vasculitis
  • intra-articular corticosteroids
  • Intracellular trafficking
  • Intravenous Golimumab
  • Intravenous immunoglobulin (IVIG)
  • intravenous immunoglobulin (IVIG) and juvenile dermatomyositis
  • intravenous immunoglobulin (IVIG) and parvovirus B19
  • intravenous immunoglobulin (IVIG) and rituximab
  • Intravenous immunoglobulin (IVIG) and scleroderma-like conditions
  • intravenous immunoglobulin (IVIG) and small fiber neuropathy
  • intravenous immunoglobulin (IVIG) and systemic lupus erythematosus (SLE)
  • intravenous immunoglobulin (IVIG) and vasculitis
  • intravenous infliximab
  • intravenous methylprednisolone
  • investigator
  • IP-10
  • IPAF
  • Ipilimumab
  • IPS (induced pluripotent stem cells)
  • iPS (induced pluripotent stem cells) and osteoarthritis
  • iPS (induced pluripotent stem cells) and tissue engineering
  • irae
  • IRF7 and glucocorticoids
  • ITK
  • Ixekizumab
  • JAK
  • Jak inhibitor
  • JAK inhibitors
  • JAK3
  • Janus kinase
  • Janus kinase (JAK)
  • Janus kinase (JAK) and collagen
  • Janus kinase (JAK) and disease-modifying antirheumatic drugs
  • Janus kinase (JAK) and drug interactions
  • Janus kinase (JAK) and Gene Expression
  • Janus kinase (JAK) and interferons
  • Janus kinase (JAK) and patient-reported outcome measures
  • Janus kinase (JAK) and pharmacokinetics
  • Janus kinase (JAK) and pharmacology
  • Janus kinase (JAK) and psoriatic arthritis
  • Janus kinase (JAK) and registry
  • Janus kinase (JAK) and rheumatoid arthritis
  • Janus kinase (JAK) and rheumatoid arthritis (RA)
  • Janus kinase (JAK) and safety
  • Janus kinase (JAK) and tofacitinib
  • Janus kinase (JAK) and transcriptional regulation
  • Janus kinase (JAK) and treatment
  • Janus kinase (JAK) and tumor necrosis factor (TNF)
  • Janus Kinase inhibitors
  • japan and safety
  • Japanese
  • Japanese and human leukocyte antigens (HLA)
  • Japanese and pharmacokinetics
  • Japanese and rheumatoid arthritis (RA)
  • Japanese and ulcers
  • JDM
  • JIA
  • job loss and juvenile idiopathic arthritis (JIA)
  • Joint
  • Joint arthroplasty
  • joint arthroplasty and osteoarthritis
  • Joint arthroplasty and pain
  • joint arthroplasty and prosthesis
  • joint arthroplasty and risk
  • joint arthroplasty and sex bias
  • joint contractures
  • joint damage
  • joint damage and Disease Activity
  • joint damage and modified stoke ankylosing spondylitis spinal score (MSASSS)
  • joint damage and MRI
  • joint damage and osteoarthritis
  • joint damage and pain
  • joint damage and pathogenesis
  • joint damage and psoriatic arthritis
  • joint damage and radiography
  • joint damage and radiology
  • joint damage and rheumatoid arthritis (RA)
  • joint damage and signal transduction
  • joint damage and spine involvement
  • joint damage and synthetase syndrome
  • joint damage and x-ray
  • joint destruction
  • joint destruction and autophagy proteins
  • joint destruction and Disease Activity
  • joint destruction and juvenile idiopathic arthritis (JIA)
  • Joint destruction and matrix metalloproteinase (MMP)
  • joint destruction and mitochondria
  • joint destruction and osteoarthritis
  • joint destruction and osteoclastogenesis
  • joint destruction and osteoclasts
  • Joint destruction and polymorphism
  • joint destruction and progression
  • joint destruction and radiography
  • joint destruction and randomized trials
  • joint destruction and rheumatoid arthritis
  • Joint destruction and rheumatoid arthritis (RA)
  • Joint effusion
  • joint inflammation
  • joint pain
  • Joint procedures
  • joint procedures and joint
  • joint procedures and juvenile idiopathic arthritis (JIA)
  • joint procedures and osteoarthritis
  • joint procedures and rheumatoid arthritis (RA)
  • joint procedures and safety
  • joint procedures and ultrasound
  • joint procedures and utilization review
  • joint protection
  • Joint replacement
  • Joint Structure
  • Journal
  • jsle
  • juvenile
  • juvenile and whole-body
  • Juvenile Arthritis
  • juvenile arthritis and accommodation
  • juvenile arthritis and cohort
  • juvenile arthritis and juvenile idiopathic arthritis (JIA)
  • juvenile arthritis and longitudinal studies
  • juvenile arthritis and magnetic resonance imaging (MRI)
  • juvenile arthritis and methotrexate (MTX)
  • Juvenile arthritis and microbiome
  • Juvenile arthritis and morbidity and mortality
  • juvenile arthritis and musculoskeletal disorders
  • juvenile arthritis and pain
  • juvenile arthritis and pediatric rheumatology
  • juvenile arthritis and polymorphism
  • Juvenile arthritis and psoriatic arthritis
  • juvenile arthritis and radiography
  • juvenile arthritis and radiology
  • juvenile arthritis and registry
  • juvenile arthritis and spondylarthritis
  • juvenile arthritis and synovial cells
  • juvenile arthritis and synovitis
  • juvenile arthritis and systemic lupus erythematosus (SLE)
  • juvenile arthritis and therapeutic targeting
  • juvenile arthritis and tocilizumab
  • juvenile arthritis and tracking
  • Juvenile arthritis and treatment
  • Juvenile arthritis and uveitis
  • juvenile arthritis and vaccines
  • juvenile arthritis and young adults
  • Juvenile Dermatomyosis
  • juvenile dermatomyositis
  • juvenile dermatomyositis and anti-mitochondria antibody
  • juvenile dermatomyositis and genomics
  • juvenile dermatomyositis and juvenile idiopathic arthritis (JIA)
  • juvenile dermatomyositis and juvenile myositis
  • juvenile dermatomyositis and lipids
  • Juvenile dermatomyositis and magnetic resonance imaging (MRI)
  • juvenile dermatomyositis and microparticles
  • juvenile dermatomyositis and mitochondria
  • Juvenile dermatomyositis and myositis
  • juvenile dermatomyositis and nailfold capillaroscopy
  • Juvenile dermatomyositis and natural killer (NK) cells
  • juvenile dermatomyositis and neutrophils
  • juvenile dermatomyositis and outcome measures
  • juvenile dermatomyositis and outcomes
  • juvenile dermatomyositis and pathogenesis
  • juvenile dermatomyositis and pediatric rheumatology
  • juvenile dermatomyositis and pediatrics
  • juvenile dermatomyositis and polymyositis/dermatomyositis (PM/DM)
  • First |
  • « Previous Page
  • 28
  • 29
  • 30
  • 31
  • 32
  • [33]
  • 34
  • 35
  • 36
  • 37
  • 38
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology